Active	Status	Sponsor type	Region	Phase	Filter
2 Active 0 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   - « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
BHV-1510 / Biohaven
NCT06384807: A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors	Recruiting	1/2	280	US	BHV-1510, PBI-410, GQ1010, Cemiplimab	Biohaven Therapeutics Ltd.	Solid Tumor	02/28	02/28
NCT06464055: A Study of GQ1010 in Subjects With Advanced Solid Tumors	Recruiting	1/2	260	RoW	Dose Escalation, Dose Expansion1, Dose Expansion2, Dose Expansion3, phase II	GeneQuantum Healthcare (Suzhou) Co., Ltd.	Advanced Malignant Solid Tumors	05/28	12/28

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
BHV-1510 / Biohaven
NCT06384807: A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors	Recruiting	1/2	280	US	BHV-1510, PBI-410, GQ1010, Cemiplimab	Biohaven Therapeutics Ltd.	Solid Tumor	02/28	02/28
NCT06464055: A Study of GQ1010 in Subjects With Advanced Solid Tumors	Recruiting	1/2	260	RoW	Dose Escalation, Dose Expansion1, Dose Expansion2, Dose Expansion3, phase II	GeneQuantum Healthcare (Suzhou) Co., Ltd.	Advanced Malignant Solid Tumors	05/28	12/28